No profile data available.
Praxis Precision Medicines, Inc. (PRAX) is a healthcare company in the brain and nerve treatment drugs industry, based in Boston, United States, with about 116 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$303.27 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $4.75 billion as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance.
Praxis Precision Medicines reported $0 in revenue for fiscal year 2025, down 100.0% from $8.55 million in fiscal year 2024. In Q2 2026 revenue was $0.
$4.75 billion as of December 4, 2025.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Alkermes plc (ALKS), PTC Therapeutics, Inc. (PTCT), Scholar Rock Holding Corporation (SRRK), Dianthus Therapeutics, Inc. (DNTH).